Cargando…
Rituximab for Rheumatoid Arthritis
Rituximab is a chimeric monoclonal antibody directed at the CD20 molecule on the surfaces of some but not all B cells. It depletes almost all peripheral B cells, but other niches of B cells are variably depleted, including synovium. Its mechanism of action in rheumatoid arthritis (RA) is only partia...
Autores principales: | Cohen, Marc D., Keystone, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883263/ https://www.ncbi.nlm.nih.gov/pubmed/27747531 http://dx.doi.org/10.1007/s40744-015-0016-9 |
Ejemplares similares
-
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
por: Cohen, Stanley B, et al.
Publicado: (2010) -
Rituximab for the treatment of rheumatoid arthritis: an update
por: Mok, Chi Chiu
Publicado: (2013) -
Rituximab and its potential for the treatment of rheumatoid arthritis
por: Bryant, Adam, et al.
Publicado: (2006) -
Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007) -
Update on the use of rituximab for intractable rheumatoid arthritis
por: Looney, R John
Publicado: (2009)